Hoffmann et al. first demonstrated that the SARS-CoV-2 S protein is primed via the TMPRSS2 protease, indicating that TMPRSS2 inhibitors may block viral invasion [9,12], SARS-CoV-2 entry, and coronavirus disease 2019 (COVID-19) outcomes [13]. Here, TMPRSS2 is linked to COVID-19.